Get the Stockscreener App
131.84
0.53%
0.70
After Hours:
131.84
Biogen Inc stock is traded at $131.84, with a volume of 1.82M.
It is up +0.53% in the last 24 hours and up +6.73% over the past month.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
See More
Previous Close:
$131.14
Open:
$130.77
24h Volume:
1.82M
Relative Volume:
1.07
Market Cap:
$19.32B
Revenue:
$9.82B
Net Income/Loss:
$1.48B
P/E Ratio:
13.01
EPS:
10.13
Net Cash Flow:
$2.30B
1W Performance:
+2.69%
1M Performance:
+6.73%
6M Performance:
-18.04%
1Y Performance:
-42.63%
1-Day Range:
$129.51
$134.74
1-Week Range:
$126.87
$134.74
52-Week Range:
$110.03
$238.00
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
131.84 | 18.81B | 9.82B | 1.48B | 2.30B | 10.13 |
|
LLY
Lilly Eli Co
|
750.78 | 651.06B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
154.42 | 368.73B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
187.25 | 328.06B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
115.94 | 223.60B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
70.91 | 312.99B | 43.59B | 15.04B | 10.74B | 3.3766 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Biogen to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - Biogen
Relapsing Remitting Multiple Sclerosis Market Set to Witness - openPR.com
Biogen Inc (BIIB)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus
Ex-Biogen Chief Medical Officer Strengthens Entrada's Duchenne Program as Phase 1 Data Shows Promise - Stock Titan
Neuromuscular Disease Therapeutics Market Growth Driven - openPR.com
152,867 Shares in Biogen Inc. (NASDAQ:BIIB) Acquired by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
First County Bank CT Makes New Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Lansforsakringar Fondforvaltning AB publ Makes New Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
City Therapeutics Partners with Biogen - Global Legal Chronicle
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen Inc. (NASDAQ:BIIB) Holdings Raised by Centre Asset Management LLC - MarketBeat
California State Teachers Retirement System Buys 2,811 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Toronto Dominion Bank Has $11.11 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Mackenzie Financial Corp Purchases 19,759 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Farmers Trust Co. Acquires 2,012 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
William Blair Brokers Lower Earnings Estimates for Biogen - MarketBeat
Lighthouse Financial LLC Makes New Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Auxier Asset Management Sells 2,136 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks - Yahoo Finance
GF Fund Management CO. LTD. Makes New $5.24 Million Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Progressive Supranuclear Palsy Treatment Market Set to Witness GrowthBiogen, AbbVie - openPR.com
PKO Investment Management Joint Stock Co Takes Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen and City Therapeutics partner to develop RNAi therapies - MSN
Biogen Inc. (NASDAQ:BIIB) Shares Sold by USS Investment Management Ltd - MarketBeat
Siemens Fonds Invest GmbH Grows Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Public Employees Retirement System of Ohio Sells 2,866 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Voloridge Investment Management LLC Invests $23.20 Million in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $234.55 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Tauopathies Treatment Market Detailed in New Research ReportBiogen, AbbVie - openPR.com
Amyotrophic lateral Sclerosis Market 2025-2032: Top Trends & - openPR.com
Recombinant Dna Technology Market Generated Opportunities, - openPR.com
In Vitro Monoclonal Antibodies Market is expected to reach US$ - openPR.com
Biogen and City Therapeutics to develop RNAi therapy - Yahoo Finance
Biogen and City Therapeutics partner to advance RNAi therapies - World Pharmaceutical Frontiers
Biogen Inc. (NASDAQ:BIIB) Holdings Lifted by Quantinno Capital Management LP - MarketBeat
Woodline Partners LP Boosts Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen’s SWOT analysis: stock faces challenges amid neuroscience potential - Investing.com
Biogen’s SWOT analysis: stock faces challenges amid neuroscience potential By Investing.com - Investing.com UK
Biogen Inc. (BIIB) Taps RNAi Therapy in City Therapeutics Deal - Yahoo Finance
Biogen (NasdaqGS:BIIB) Partners With City Therapeutics in US$1 Billion RNAi Therapy Deal - simplywall.st
Biogen partners with John Maraganore’s new RNAi startup - The Business Journals
Biogen (BIIB) Partners with City Therapeutics for RNAi Therapies - GuruFocus
Biogen strikes RNAi deal with City; Aurion withdraws IPO - BioPharma Dive
City hits the town with $1B-plus deal with Biogen - BioWorld MedTech
Biogen and City Therapeutics collaborate on RNAi meds - The Pharma Letter
Biogen taps City Therapeutics in RNAi deal worth up to $1B - Endpoints News
Biogen (BIIB) Collaborates with City Therapeutics on RNAi Therap - GuruFocus
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
0.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):